ESC 365 - Comparing PCSK9 inhibitor prescription rates within high-risk populations: diabetes mellitus, multi-territory vascular disease, multivessel and recurrent coronary artery disease

ESC Professional Premium Access

Comparing PCSK9 inhibitor prescription rates within high-risk populations: diabetes mellitus, multi-territory vascular disease, multivessel and recurrent coronary artery disease

Session: Lifestyle, obesity, and dyslipidaemia

Topic: Secondary Prevention

Speaker: Doctor W. He (Melbourne, AU)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor William Biao He

The Alfred Hospital, Melbourne (Australia)

1 presentation

0 follower

4 more presentations in this session

The impact of pre-myocardial infarction exercise frequency on prognosis in acute myocardial infarction patients

Speaker: Doctor T. Gu (Tianjin, CN)

Revisiting the obesity paradox: lean body mass, fat mass, and mortality in patients with atrial fibrillation

Speaker: Professor Y. Lu (Shanghai, CN)

High discontinuation rate of statins among PCSK9i users: a nationwide study from 2015-2023

Speaker: Ms I. Engebretsen (Oslo, NO)

Association between achieved cholesterol levels and the risk of major adverse cardiovascular events after acute coronary syndromes

Speaker: Mr C. Follonier (Geneva, CH)

Access the full session

Lifestyle, obesity, and dyslipidaemia

Speakers: Doctor W. He, Doctor T. Gu, Professor Y. Lu, Ms I. Engebretsen, Mr C. Follonier

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources